Secarna pharmaceuticals and achilles therapeutics sign research, option and license agreement to develop optimized t cell therapies

Secarna's lnaplustm asos have the potential to optimize personalized t cell therapies being developed by achilles secarna's industry-leading antisense oligonucleotide (aso) platform lnaplustm enables discovery and research of asos against undisclosed targets in the area of immune oncology munich, germany and martinsried, germany / accesswire / november 10, 2021 / secarna pharmaceuticals gmbh & co. kg ("secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (aso) therapies to address challenging or previously undruggable targets, today announced that the company has entered into a research, option and license agreement with achilles therapeutics uk limited ("achilles"), a member of the achilles therapeutics plc (nasdaq:achl) group of companies, in the field of immune oncology. secarna will employ its commercially validated discovery and development platform, lnaplustm, to generate aso candidates against selected targets that potentially play a central role in the ex vivo optimization of personalized t cell therapies being developed by achilles.
ACHL Ratings Summary
ACHL Quant Ranking